CAREDX INC (CDNA) Stock Fundamental Analysis
NASDAQ:CDNA - Nasdaq - US14167L1035 - Common Stock - Currency: USD
CDNA gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. CDNA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CDNA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year CDNA was profitable.
In the past year CDNA had a positive cash flow from operations.
CDNA had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CDNA reported negative operating cash flow in multiple years.
1.2 Ratios
CDNA's Return On Assets of 12.02% is amongst the best of the industry. CDNA outperforms 95.50% of its industry peers.
CDNA has a Return On Equity of 15.51%. This is amongst the best in the industry. CDNA outperforms 95.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.02% | ||
| ROE | 15.51% | ||
| ROIC | N/A |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDNA's Profit Margin of 16.99% is amongst the best of the industry. CDNA outperforms 94.78% of its industry peers.
With an excellent Gross Margin value of 67.64%, CDNA belongs to the best of the industry, outperforming 81.30% of the companies in the same industry.
CDNA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.99% | ||
| GM | 67.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDNA has been increased compared to 1 year ago.
The number of shares outstanding for CDNA has been increased compared to 5 years ago.
There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 2.86 indicates that CDNA is not a great score, but indicates only limited risk for bankruptcy at the moment.
CDNA's Altman-Z score of 2.86 is fine compared to the rest of the industry. CDNA outperforms 72.84% of its industry peers.
There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 2.86 |
ROIC/WACCN/A
WACC9.77%
2.3 Liquidity
A Current Ratio of 4.11 indicates that CDNA has no problem at all paying its short term obligations.
CDNA has a Current ratio of 4.11. This is comparable to the rest of the industry: CDNA outperforms 46.76% of its industry peers.
CDNA has a Quick Ratio of 3.84. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
CDNA has a Quick ratio (3.84) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.11 | ||
| Quick Ratio | 3.84 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 217.86% over the past year.
CDNA shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 37.47% yearly.
CDNA shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.92%.
CDNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.30% yearly.
EPS 1Y (TTM)217.86%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%400%
Revenue 1Y (TTM)25.92%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%17.54%
3.2 Future
Based on estimates for the next years, CDNA will show a very strong growth in Earnings Per Share. The EPS will grow by 39.74% on average per year.
Based on estimates for the next years, CDNA will show a quite strong growth in Revenue. The Revenue will grow by 13.46% on average per year.
EPS Next Y13.3%
EPS Next 2Y42.1%
EPS Next 3Y39.74%
EPS Next 5YN/A
Revenue Next Year11.91%
Revenue Next 2Y13.67%
Revenue Next 3Y13.46%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
CDNA is valuated rather expensively with a Price/Earnings ratio of 19.32.
Compared to the rest of the industry, the Price/Earnings ratio of CDNA indicates a rather cheap valuation: CDNA is cheaper than 95.50% of the companies listed in the same industry.
CDNA is valuated rather cheaply when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 11.69 indicates a reasonable valuation of CDNA.
96.04% of the companies in the same industry are more expensive than CDNA, based on the Price/Forward Earnings ratio.
CDNA's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.32 | ||
| Fwd PE | 11.69 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, CDNA is valued cheaper than 93.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.23 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
CDNA's earnings are expected to grow with 39.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.45
PEG (5Y)0.52
EPS Next 2Y42.1%
EPS Next 3Y39.74%
5. Dividend
5.1 Amount
No dividends for CDNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.75
+0.84 (+7.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.56%
Inst Owner Change-0.05%
Ins Owners2.25%
Ins Owner Change4.74%
Market Cap709.92M
Analysts80
Price Target30.16 (136.55%)
Short Float %11.89%
Short Ratio5.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.65%
Min EPS beat(2)36.04%
Max EPS beat(2)37.26%
EPS beat(4)4
Avg EPS beat(4)404.01%
Min EPS beat(4)36.04%
Max EPS beat(4)1272.55%
EPS beat(8)8
Avg EPS beat(8)229.71%
EPS beat(12)11
Avg EPS beat(12)158.53%
EPS beat(16)13
Avg EPS beat(16)133.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.35%
Min Revenue beat(2)-1.61%
Max Revenue beat(2)0.91%
Revenue beat(4)3
Avg Revenue beat(4)8.38%
Min Revenue beat(4)-1.61%
Max Revenue beat(4)33.31%
Revenue beat(8)7
Avg Revenue beat(8)10.24%
Revenue beat(12)7
Avg Revenue beat(12)5.45%
Revenue beat(16)9
Avg Revenue beat(16)4.44%
PT rev (1m)3.31%
PT rev (3m)-7.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.34%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.32 | ||
| Fwd PE | 11.69 | ||
| P/S | 2.05 | ||
| P/FCF | 35.23 | ||
| P/OCF | 26.51 | ||
| P/B | 1.87 | ||
| P/tB | 2.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.66
EY5.18%
EPS(NY)1.09
Fwd EY8.55%
FCF(TTM)0.36
FCFY2.84%
OCF(TTM)0.48
OCFY3.77%
SpS6.22
BVpS6.81
TBVpS5.42
PEG (NY)1.45
PEG (5Y)0.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.02% | ||
| ROE | 15.51% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.99% | ||
| GM | 67.64% | ||
| FCFM | 5.82% |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
F-Score6
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 47.43% | ||
| Cap/Sales | 1.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 34.24% | ||
| Current Ratio | 4.11 | ||
| Quick Ratio | 3.84 | ||
| Altman-Z | 2.86 |
F-Score6
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)106.55%
Cap/Depr(5y)139.53%
Cap/Sales(3y)4.27%
Cap/Sales(5y)5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)217.86%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%400%
EPS Next Y13.3%
EPS Next 2Y42.1%
EPS Next 3Y39.74%
EPS Next 5YN/A
Revenue 1Y (TTM)25.92%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%17.54%
Revenue Next Year11.91%
Revenue Next 2Y13.67%
Revenue Next 3Y13.46%
Revenue Next 5YN/A
EBIT growth 1Y57.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year132.16%
EBIT Next 3Y84.29%
EBIT Next 5YN/A
FCF growth 1Y193.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y963.74%
OCF growth 3YN/A
OCF growth 5YN/A